Security key
09075P204
BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI)
CUSIP: 09075P204
Q2 2025 13F Holders as of 30 Jun 2025
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 603,081
- Total 13F value
- $1,090,541
- Share change
- +224,098
- SEC-reported price per share
- $1.81
- Number of holders
- 33
- Value change
- +$395,829
- Number of buys
- 14
- Number of sells
- 13
- Shares outstanding
- 21,847,524
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2025
Institutions
33
Top holders
10
BTAI full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
BioXcel Therapeutics, Inc. SEC filings
BioXcel Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 09075P204
Recent filing periods:
Ownership snapshot
Top reported holders of BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ARMISTICE CAPITAL, LLC
Disclosed value leader
ARMISTICE CAPITAL, LLC
Comparable rows
15/15
Latest evidence
31 Mar 2025
13D/G
13F
Lead comparable stake: 5%
13D/G row: ARMISTICE CAPITAL, LLC
Showing 1-6 of 15 holder rows.
Quick read
ARMISTICE CAPITAL, LLC leads the comparable SEC ownership view at 5%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ARMISTICE CAPITAL, LLC's linked filing trail.
Comparable ownership
Top 5
ARMISTICE CAPITAL, LLC
5%
Oaktree Capital Group Holdings GP...
2.7%
Murchinson Ltd.
0.62%
UBS Group AG
0.47%
GOLDMAN SACHS GROUP INC
0.11%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC |
13D/G
|
5%
|
$564,737
288,131 shares
|
-$9,229,922 | 31 Mar 2025 |
| Oaktree Capital Group Holdings GP, LLC |
13D/G
Oaktree Capital Holdings, LLC
|
2.7%
|
$28,939
170,230 shares
|
-$434,154 | 31 Mar 2025 |
| Murchinson Ltd. |
13F
Company
|
0.62%
|
$276,234
136,076 shares
|
— | 31 Mar 2025 |
| UBS Group AG |
13F
Company
|
0.47%
|
$206,609
101,778 shares
|
— | 31 Mar 2025 |
| GOLDMAN SACHS GROUP INC |
13F
Company
|
0.11%
|
$50,332
24,794 shares
|
— | 31 Mar 2025 |
| BlackRock, Inc. |
13F
Company
|
0.11%
|
$47,179
23,241 shares
|
— | 31 Mar 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
33
Shares
603,081
Rows available
33
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2025 vs Q1 2026 Across Filers
Q1 2026 holders
40
Q2 2025 holders
33
Holder diff
-7
| Investor | Q1 2026 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend